Prestige Consumer Healthcare (PBH) Projected to Post Quarterly Earnings on Wednesday

Prestige Consumer Healthcare (NYSE:PBH) is expected to announce its Q4 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $1.39 per share and revenue of $293.7340 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare Trading Down 3.8%

Shares of PBH opened at $50.53 on Tuesday. The business has a 50-day moving average of $59.50 and a 200 day moving average of $61.77. Prestige Consumer Healthcare has a fifty-two week low of $49.28 and a fifty-two week high of $89.37. The firm has a market cap of $2.39 billion, a P/E ratio of 13.37, a price-to-earnings-growth ratio of 1.57 and a beta of 0.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PBH shares. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Oppenheimer decreased their price objective on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Jefferies Financial Group decreased their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.75.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 2,553 shares of company stock worth $151,444. Company insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently modified their holdings of PBH. AQR Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock valued at $2,558,000 after acquiring an additional 3,200 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after acquiring an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after acquiring an additional 70,330 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its position in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after buying an additional 269 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).